Comparison of clinicopathologic variables in coexistence cancers of the endometrium and ovary: A review of 55 cases in an academic center in Iran

• Published in: Journal of research in medical sciences Vol. 20; no. 8; pp. 727 - 732
• Main Authors: Sadidi, Hossein, Izadi-Mood, Narges, Sarmadi, Soheila, Yarandi, Fariba, Amini-Moghaddam, Soheila, Esfahani, Fatemeh, Sadidi, Mohammad
• Format: Journal Article
• Language: English
• Published: India Medknow Publications Pvt Ltd 01.08.2015; Medknow Publications & Media Pvt. Ltd; Medknow Publications & Media Pvt Ltd; Wolters Kluwer Medknow Publications
• Subjects: Coexistent disease; disease-free survival; endometrium carcinomas; neoplasm grading; neoplasm staging; Original; ovarian cancer; neoplasm grading; Coexistent disease; neoplasm staging; disease-free survival; ovarian cancer; endometrium carcinomas
• ISSN: 1735-1995; 1735-1995; 1735-7136
• DOI: 10.4103/1735-1995.168315

Background: The coexistence primary cancers of the endometrium and ovary are relatively uncommon. The purpose of this study was to characterize patients diagnosed primary synchronous endometrial and ovarian cancer (SEOC), endometrial cancer (EC) with ovarian metastasis, and ovarian cancer (OC) with endometrial metastasis and compare clinicopathologic variables and prognosis. Materials and Methods: All the patients with diagnosis of both endometrium and OC, who hospitalized between 2002 and 2012 in an academic center affiliated to Tehran University of Medical Sciences, were evaluated with respect to different clinicopathologic variables, follow-up times, and outcomes. Results: Fifty-five patients had been diagnosed with both endometrium and OC. 17, 26, and 12 patients were diagnosed as SEOC, EC, and OC, respectively. The frequency of abnormal uterine bleeding was significantly lower in OC (16.7%) compared to others (58.8% in SEOC and 53.8% in EC). However, the abdominal/pelvic pain was significantly higher in OC (50%) compared to others (35.3% in SEOC and 34.6% in EC) (P < 0.05). Complex atypical hyperplasia (87.5%), endometriosis (88.8%), and endometrioid carcinoma (54.5%) was observed most in SEOC group. The duration of follow-up time was between 3 and 171 months with a mean of 16 months. There was no death in SEOC who followed. Survivals of patients between three group were statistically significant (P = 0.032). Conclusion: Our results showed that overall survival (OS) and progression-free survival (PFS) of SEOC patients is better than those with EC and OC (P = 0.032).